Long-term Outcome of Pediatric Patients with Severe Aplastic Anemia Treated with Antithymocyte Globulin and Cyclosporine

Overview

Journal J Pediatr

Specialty Pediatrics

Date 2008 Aug 2

PMID 18672253

Citations 44

Authors

Phillip Scheinberg

Colin O Wu

Olga Nunez

Neal S Young

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the long-term outcomes in children with severe aplastic anemia (SAA) treated with antithymocyte globulin (ATG) and cyclosporine (CsA) through a retrospective analysis of the pediatric patients treated at our institution in all protocols that included horse ATG (h-ATG) and CsA.

Study Design: Between 1989 and 2006, a total of 406 patients, 20% of whom were children under age 18 years, received an initial course of immunosuppressive therapy (IST) at our institution. Here we report the outcome of 77 children who were treated with an h-ATG plus CsA-based regimen during this period.

Results: The overall response rate at 6 months was 74% (57/77); the cumulative incidence of relapse at 10 years was 33%, and the median time to relapse was 558 days. The cumulative incidence of evolution after IST was 8.5%; all 3 such events occurred in partial responders. Overall, there were 13 deaths (17%), with 4 occurring within the 3 months after IST in patients who had a pretreatment absolute neutrophil count of < 100/microL and the other 9 occurring more than 6 months after initiation of IST. The median time to death was 570 days. The overall 10-year survival for the entire cohort was 80%; long-term survival in the children who responded to IST was 89%.

Conclusions: The long-term survival in pediatric patients who respond to IST is excellent, at about 90%. IST remains a good alternative in pediatric patients who lack an HLA-matched sibling donor and should be offered as initial therapy before possible hematopoietic stem cell transplantation from an unrelated donor.

Citing Articles

Eltrombopag combined with immunosuppressive therapy for pediatric severe aplastic anemia.

Yang B, Fu L, Li H, Chen H, Zhang R, Yao J Pediatr Res. 2024; .

PMID: 38822136 DOI: 10.1038/s41390-024-03253-w.

The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults.

Piekarska A, Pawelec K, Szmigielska-Kaplon A, Ussowicz M Front Immunol. 2024; 15:1378432.

PMID: 38646536 PMC: 11026616. DOI: 10.3389/fimmu.2024.1378432.

Incidence of drug-related adverse events related to the use of high-alert drugs: A systematic review of randomized controlled trials.

Menezes M, Doria G, Valenca-Feitosa F, Pereira S, Silvestre C, de Oliveira Filho A Explor Res Clin Soc Pharm. 2024; 14:100435.

PMID: 38646469 PMC: 11031819. DOI: 10.1016/j.rcsop.2024.100435.

Progress in medical therapy in aplastic anemia: why it took so long?.

Scheinberg P Int J Hematol. 2024; 119(3):248-254.

PMID: 38403842 DOI: 10.1007/s12185-024-03713-3.

Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival.

Chattopadhyay S, Lionel S, Selvarajan S, Devasia A, Korula A, Kulkarni U Ann Hematol. 2024; 103(3):749-758.

PMID: 38242970 DOI: 10.1007/s00277-024-05621-2.

References

Dunn D, Tanawattanacharoen P, Boccuni P, Nagakura S, Green S, Kirby M . Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999; 131(6):401-8. DOI: 10.7326/0003-4819-131-6-199909210-00002. View

Scheinberg P, Nunez O, Wu C, Young N . Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol. 2006; 133(6):606-11. DOI: 10.1111/j.1365-2141.2006.06085.x. View

Ades L, Mary J, Robin M, Ferry C, Porcher R, Esperou H . Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2003; 103(7):2490-7. DOI: 10.1182/blood-2003-07-2546. View

Horowitz M . Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol. 2000; 37(1):30-42. DOI: 10.1016/s0037-1963(00)90028-3. View

Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G . Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005; 106(6):2102-4. DOI: 10.1182/blood-2005-03-0874. View

Rosenfeld S, Follmann D, Nunez O, Young N . Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003; 289(9):1130-5. DOI: 10.1001/jama.289.9.1130. View

Locasciulli A, Veer L, Bacigalupo A, Hows J, Van Lint M, Gluckman E . Treatment with marrow transplantation or immunosuppression of childhood acquired severe aplastic anemia: a report from the EBMT SAA Working Party. Bone Marrow Transplant. 1990; 6(3):211-7. View

Frickhofen N, Rosenfeld S . Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol. 2000; 37(1):56-68. DOI: 10.1016/s0037-1963(00)90030-1. View

Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A . Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007; 92(1):11-8. DOI: 10.3324/haematol.10075. View

10.

Yamaguchi H, Calado R, Ly H, Kajigaya S, Baerlocher G, Chanock S . Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005; 352(14):1413-24. DOI: 10.1056/NEJMoa042980. View

11.

Gillio A, Boulad F, Small T, Kernan N, Reyes B, Childs B . Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation. Biol Blood Marrow Transplant. 1997; 3(1):18-24. View

12.

Gillio A, Verlander P, Batish S, Giampietro P, Auerbach A . Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study. Blood. 1997; 90(1):105-10. View

13.

Fuhrer M, Burdach S, Ebell W, Gadner H, Haas R, Harbott J . Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group. Klin Padiatr. 1998; 210(4):173-9. DOI: 10.1055/s-2008-1043875. View

14.

Fogarty P, Yamaguchi H, Wiestner A, Baerlocher G, Sloand E, Zeng W . Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet. 2003; 362(9396):1628-30. DOI: 10.1016/S0140-6736(03)14797-6. View

15.

Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A . Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002; 100(3):799-803. DOI: 10.1182/blood.v100.3.799. View

16.

Kennedy-Nasser A, Leung K, Mahajan A, Weiss H, Arce J, Gottschalk S . Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006; 12(12):1277-84. DOI: 10.1016/j.bbmt.2006.07.011. View

17.

Bayever E, Champlin R, Ho W, Lenarsky C, Storch S, Ladisch S . Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia. J Pediatr. 1984; 105(6):920-5. DOI: 10.1016/s0022-3476(84)80078-5. View

18.

Rosenfeld S, Kimball J, Vining D, Young N . Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995; 85(11):3058-65. View

19.

Passweg J, Perez W, Eapen M, Camitta B, Gluckman E, Hinterberger W . Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant. 2006; 37(7):641-9. DOI: 10.1038/sj.bmt.1705299. View

20.

Halperin D, Grisaru D, Freedman M, Saunders E . Severe acquired aplastic anemia in children: 11-year experience with bone marrow transplantation and immunosuppressive therapy. Am J Pediatr Hematol Oncol. 1989; 11(3):304-9. View